A recombinant enzyme that enhances the activity of the body’s natural antithrombotic, thrombolytic and cytoprotective defense systems. AB002 is in development for use in acute cardiovascular events and other indications, and is currently being tested in a phase 2 clinical trial.
A recombinant monoclonal antibody that selectively inhibits the activation of coagulation factor IX (F9) by coagulation factor XI (F11). AB012 is in early clinical trial stage with a partner company for use in vascular and other indications.
A recombinant monoclonal antibody that selectively inhibits assembly of the blood contact activation complex. AB023 is in phase 2 clinical trial stage of development. Intended indications for AB023 include long, medium, or short-term use in a broad range of cardiovascular, hematological, infectious, and neurological indications.
A recombinant monoclonal antibody that selectively inhibits the activity of the contact activation enzyme of blood. AB054 is in pre-clinical development stage for acute and short-term use during extracorporeal organ support, severe infections, select allergies, and other indications.
An antisense oligonucleotide that reduces the synthesis of a glycoprotein hormone. AB062 is in early pre-
clinical development with a partner company for multiple indications, including cardiovascular and neoplastic